Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Biomea Fusion Inc. currently manages 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners, meaning each pending matter is under the review of a different individual. Despite this distribution, the portfolio is concentrated within 1 distinct art unit. This concentration suggests that while different individuals are reviewing the applications, they are all part of the same specialized technical group at the patent office. The 3 pending office actions represent the company's current efforts to expand its intellectual property in the biotechnology sector.
WHITE, DAWANNA SHAR-DAY is identified as the busiest examiner for the company, currently handling 1 pending office action. This single action represents the maximum workload assigned to any individual examiner within the portfolio. The alignment of 3 distinct examiners with 3 pending office actions suggests a broad exposure to different examiner perspectives within the constraints of 1 distinct art unit. This structure allows the company to receive feedback from multiple reviewers while remaining within a single technical discipline. Such a distribution ensures that no 1 examiner has a concentrated influence over the company's pending applications.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (33%) |
| Double-patenting + other | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WHITE, DAWANNA SHAR-DAY | 1 | 62.5% | +23.3% |
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.7% |
| ROMERO, KRISTEN WANG | 1 | 68.8% | +31.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18768954 | N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-d]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO-2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINE CARBOXAMIDE AND USES THEREOF | WILLIS, DOUGLAS M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18871252 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN | WHITE, DAWANNA SHAR-DAY | — |
| 18768954 | N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-d]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO-2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINE CARBOXAMIDE AND USES THEREOF | WILLIS, DOUGLAS M | — |
| 18257541 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN-MLL INTERACTION | ROMERO, KRISTEN WANG | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18871252 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN | WHITE, DAWANNA SHAR-DAY | — | §103§112DP | Non-Final OA | — | Pending | Dec 03, 2024 |
| 18768954 | N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-d]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO-2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINE CARBOXAMIDE AND USES THEREOF | WILLIS, DOUGLAS M | — | DP | Non-Final OA | — | Pending | Jul 10, 2024 |
| 18257541 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN-MLL INTERACTION | ROMERO, KRISTEN WANG | 1624 | §112DP | Final Rejection | — | Pending | Jun 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial